|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
1994-11-10
|
|
pubmed:abstractText |
Mutational inactivation and allelic loss of the von Hippel-Lindau (VHL) gene appear to be causal events for the majority of spontaneous clear-cell renal carcinomas. We now show that hypermethylation of a normally unmethylated CpG island in the 5' region provides another potentially important mechanism for inactivation of the VHL gene in a significant portion of these cancers. This hypermethylation was found in 5 of 26 (19%) tumors examined. Four of these had lost one copy of VHL while one retained two heavily methylated alleles. Four of the tumors with VHL hypermethylation had no detectable mutations, whereas one had a missense mutation in addition to hypermethylation of the single retained allele. As would be predicted for the consequence of methylation in this 5' CpG island, none of the 5 tumors expressed the VHL gene. In contrast, normal kidney and all tumors examined with inactivating VHL gene mutations but no CpG island methylation had expression. In a renal cell culture line, treatment with 5-aza-2'-deoxycytidine resulted in reexpression of the VHL gene. These findings suggest that aberrant methylation of CpG islands may participate in the tumor-suppressor gene inactivations which initiate or cause progression of common human cancers.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-1345811,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-1347428,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-1369742,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-1659741,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-1671000,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-1671759,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-1673287,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-1777359,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-1974172,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-2014266,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-2039823,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-2385586,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-2418016,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-2423876,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-2550354,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-2579435,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-2840671,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-2885753,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-3342396,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-7690336,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-8094071,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-8187067,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-8242636,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-8247133,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-8331684,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-8371415,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-8389241,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-8455933,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-8462104,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-8469285,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-8493574,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7937876-8504410
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0027-8424
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
11
|
|
pubmed:volume |
91
|
|
pubmed:geneSymbol |
VHL
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
9700-4
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:7937876-Adenocarcinoma, Clear Cell,
pubmed-meshheading:7937876-Base Sequence,
pubmed-meshheading:7937876-Carcinoma, Renal Cell,
pubmed-meshheading:7937876-Chromosome Aberrations,
pubmed-meshheading:7937876-DNA, Neoplasm,
pubmed-meshheading:7937876-DNA Primers,
pubmed-meshheading:7937876-Dinucleoside Phosphates,
pubmed-meshheading:7937876-Exons,
pubmed-meshheading:7937876-Genes, Tumor Suppressor,
pubmed-meshheading:7937876-Humans,
pubmed-meshheading:7937876-Kidney Neoplasms,
pubmed-meshheading:7937876-Methylation,
pubmed-meshheading:7937876-Molecular Sequence Data,
pubmed-meshheading:7937876-Mutation,
pubmed-meshheading:7937876-Polymerase Chain Reaction,
pubmed-meshheading:7937876-Restriction Mapping
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.
|
|
pubmed:affiliation |
Oncology Center, Johns Hopkins Medical Institutions, Baltimore, MD 21231.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
